BioCentury | May 17, 2019
Company News

Management tracks: AstraZeneca, Certara, Longas

...of microarray company Solexa Inc. in 2000-05. Spun out of the ithree institute at the University of Technology Sydney...
BioCentury | Mar 7, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

...identified an N-acylamino acid-based inhibitor of SLC6A5 that could help treat chronic neuropathic pain The University of Technology Sydney...
BioCentury | Feb 11, 2019
Distillery Therapeutics

Neurology

...University of Technology Sydney, Sydney, Australia email: tristan.rawling@uts.edu.au CONTACT: Robert J. Vandenberg, same affiliation as above email: robert.vandenberg@sydney.edu.au Claire Quang University of Technology Sydney Solute...
BioCentury | Nov 11, 2016
Emerging Company Profile

Golden opportunity

...targets,” CSO Neil Miller told BioCentury. Scientific co-founders Ian Charles and Dagmar Alber at the University of Technology Sydney...
...Institutions Mentioned Auspherix Ltd., Stevenage, U.K. U.S. Food and Drug Administration (FDA), Silver Spring, Md. University of Technology Sydney...
BioCentury | Dec 18, 2014
Translation in Brief

YABAO GOES BOLD

Yabao goes bold China-based Yabao Pharmaceutical Group Co. Ltd. and MRC Technology are jointly going where Western pharmas and academics fear to tread with a preclinical partnership to develop compounds against an undisclosed kinase target...
BioCentury | Nov 3, 2014
Company News

Nuvilex, University of Veterinary Medicine deal

Nuvilex and the university partnered to conduct preclinical studies of Nuvilex's Cell-in-a-Box cellulose-based, live-cell encapsulation technology to treat diabetes under a two-year initial deal. The university will evaluate the tumorigenicity of an insulin-producing cell line,...
BioCentury | Dec 9, 2013
Company News

Auspherix infectious news

...treat resistant bacterial diseases. The newco will in-license IP from the ithree institute at the University of Technology Sydney...
BioCentury | Dec 4, 2013
Financial News

Auspherix debuts with funding from MRCF

...treat resistant bacterial diseases. The newco will in-license IP from the ithree institute at the University of Technology Sydney...
BioCentury | Feb 18, 2013
Company News

Helmedix autoimmune news

...treat autoimmune diseases. The newco is based on IP from the ithree institute at the University of Technology Sydney...
BioCentury | Feb 15, 2013
Financial News

Helmedix debuts with funding from MRCF

...treat autoimmune diseases. The newco is based on IP from the ithree institute at the University of Technology Sydney...
Items per page:
1 - 10 of 11
BioCentury | May 17, 2019
Company News

Management tracks: AstraZeneca, Certara, Longas

...of microarray company Solexa Inc. in 2000-05. Spun out of the ithree institute at the University of Technology Sydney...
BioCentury | Mar 7, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

...identified an N-acylamino acid-based inhibitor of SLC6A5 that could help treat chronic neuropathic pain The University of Technology Sydney...
BioCentury | Feb 11, 2019
Distillery Therapeutics

Neurology

...University of Technology Sydney, Sydney, Australia email: tristan.rawling@uts.edu.au CONTACT: Robert J. Vandenberg, same affiliation as above email: robert.vandenberg@sydney.edu.au Claire Quang University of Technology Sydney Solute...
BioCentury | Nov 11, 2016
Emerging Company Profile

Golden opportunity

...targets,” CSO Neil Miller told BioCentury. Scientific co-founders Ian Charles and Dagmar Alber at the University of Technology Sydney...
...Institutions Mentioned Auspherix Ltd., Stevenage, U.K. U.S. Food and Drug Administration (FDA), Silver Spring, Md. University of Technology Sydney...
BioCentury | Dec 18, 2014
Translation in Brief

YABAO GOES BOLD

Yabao goes bold China-based Yabao Pharmaceutical Group Co. Ltd. and MRC Technology are jointly going where Western pharmas and academics fear to tread with a preclinical partnership to develop compounds against an undisclosed kinase target...
BioCentury | Nov 3, 2014
Company News

Nuvilex, University of Veterinary Medicine deal

Nuvilex and the university partnered to conduct preclinical studies of Nuvilex's Cell-in-a-Box cellulose-based, live-cell encapsulation technology to treat diabetes under a two-year initial deal. The university will evaluate the tumorigenicity of an insulin-producing cell line,...
BioCentury | Dec 9, 2013
Company News

Auspherix infectious news

...treat resistant bacterial diseases. The newco will in-license IP from the ithree institute at the University of Technology Sydney...
BioCentury | Dec 4, 2013
Financial News

Auspherix debuts with funding from MRCF

...treat resistant bacterial diseases. The newco will in-license IP from the ithree institute at the University of Technology Sydney...
BioCentury | Feb 18, 2013
Company News

Helmedix autoimmune news

...treat autoimmune diseases. The newco is based on IP from the ithree institute at the University of Technology Sydney...
BioCentury | Feb 15, 2013
Financial News

Helmedix debuts with funding from MRCF

...treat autoimmune diseases. The newco is based on IP from the ithree institute at the University of Technology Sydney...
Items per page:
1 - 10 of 11